Facebook Twitter LinkedIn Instagram Email Printer Google Plus

Consumerism

Hospital systems will be in a precarious position if they all aim for the same North Star. What might their evolution look like in coming years?

Partner, Health & Life Sciences, Oliver Wyman
Principal, Health & Life Sciences, Oliver Wyman

Purposeful collaboration will help more people understand how their daily decisions dictate their health.

Principal, Oliver Wyman

It’s not yet known how blockchain will affect the health market. But is healthcare’s blockchain hype justified or just to be set aside?

Co-Founder and CTO, PokitDok

What missed opportunities will incumbents one day wish they had taken advantage of? Adopting a new mentality will disrupt the industry from the inside out.

Principal, Health & Life Sciences, Oliver Wyman
Partner, Health & Life Sciences, Oliver Wyman

2018 has already seen transformational industry news. Here we dig deeper and analyze what the industry can expect in M&A, investments, pharma and much more.

Partner, Health & Life Sciences, Oliver Wyman
Managing Partner, Health & Life Sciences, Oliver Wyman

Insights in your inbox

Subscribe

What's around the bend for healthcare venture capital in 2018? We talk Amazon, good and bad M&A, and hitting the investment peak.

Senior Managing Director, GE Ventures

CVS, Aetna, and UnitedHealthcare are just a few leading names that may forever change healthcare delivery. Should traditional health systems cling to the status quo or go with the flow?

Partner, Health & Life Sciences, Oliver Wyman

What some of healthcare’s most influential voices had to say about the past, present, and future of the industry on the Summit's final day.

Disruption in healthcare will be driven by the power of its trapped – and highly exploitable – value.

Partner, Health & Life Sciences, Oliver Wyman
Partner, Health & Life Sciences, Oliver Wyman
Managing Partner, Health & Life Sciences, Oliver Wyman

Insights from the Summit’s Executive Sessions where speakers dove deep into topics like consumerism, pharma, the future of trading flow, and artificial intelligence.

Insights in your inbox

Subscribe